
Global COX-2 Selective NSAIDs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global COX-2 Selective NSAIDs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for COX-2 Selective NSAIDs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for COX-2 Selective NSAIDs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for COX-2 Selective NSAIDs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for COX-2 Selective NSAIDs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of COX-2 Selective NSAIDs include Teva, Merck, Mylan, Jiangsu Hengrui Medicine, Pfizer, Lupin and Apotex, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for COX-2 Selective NSAIDs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of COX-2 Selective NSAIDs, also provides the sales of main regions and countries. Of the upcoming market potential for COX-2 Selective NSAIDs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the COX-2 Selective NSAIDs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global COX-2 Selective NSAIDs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for COX-2 Selective NSAIDs sales, projected growth trends, production technology, application and end-user industry.
COX-2 Selective NSAIDs Segment by Company
Teva
Merck
Mylan
Jiangsu Hengrui Medicine
Pfizer
Lupin
Apotex
COX-2 Selective NSAIDs Segment by Type
Valdecoxib
Rofecoxib
Celecoxib
Etoricoxib
COX-2 Selective NSAIDs Segment by Application
Hospital
Clinic
Other
COX-2 Selective NSAIDs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global COX-2 Selective NSAIDs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of COX-2 Selective NSAIDs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of COX-2 Selective NSAIDs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the COX-2 Selective NSAIDs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of COX-2 Selective NSAIDs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of COX-2 Selective NSAIDs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of COX-2 Selective NSAIDs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global COX-2 Selective NSAIDs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for COX-2 Selective NSAIDs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for COX-2 Selective NSAIDs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for COX-2 Selective NSAIDs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for COX-2 Selective NSAIDs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of COX-2 Selective NSAIDs include Teva, Merck, Mylan, Jiangsu Hengrui Medicine, Pfizer, Lupin and Apotex, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for COX-2 Selective NSAIDs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of COX-2 Selective NSAIDs, also provides the sales of main regions and countries. Of the upcoming market potential for COX-2 Selective NSAIDs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the COX-2 Selective NSAIDs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global COX-2 Selective NSAIDs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for COX-2 Selective NSAIDs sales, projected growth trends, production technology, application and end-user industry.
COX-2 Selective NSAIDs Segment by Company
Teva
Merck
Mylan
Jiangsu Hengrui Medicine
Pfizer
Lupin
Apotex
COX-2 Selective NSAIDs Segment by Type
Valdecoxib
Rofecoxib
Celecoxib
Etoricoxib
COX-2 Selective NSAIDs Segment by Application
Hospital
Clinic
Other
COX-2 Selective NSAIDs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global COX-2 Selective NSAIDs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of COX-2 Selective NSAIDs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of COX-2 Selective NSAIDs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the COX-2 Selective NSAIDs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of COX-2 Selective NSAIDs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of COX-2 Selective NSAIDs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of COX-2 Selective NSAIDs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
183 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global COX-2 Selective NSAIDs Market Size, 2020 VS 2024 VS 2031
- 1.3 Global COX-2 Selective NSAIDs Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global COX-2 Selective NSAIDs Sales Estimates and Forecasts (2020-2031)
- 1.5 Global COX-2 Selective NSAIDs Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global COX-2 Selective NSAIDs Market Dynamics
- 2.1 COX-2 Selective NSAIDs Industry Trends
- 2.2 COX-2 Selective NSAIDs Industry Drivers
- 2.3 COX-2 Selective NSAIDs Industry Opportunities and Challenges
- 2.4 COX-2 Selective NSAIDs Industry Restraints
- 3 COX-2 Selective NSAIDs Market by Manufacturers
- 3.1 Global COX-2 Selective NSAIDs Revenue by Manufacturers (2020-2025)
- 3.2 Global COX-2 Selective NSAIDs Sales by Manufacturers (2020-2025)
- 3.3 Global COX-2 Selective NSAIDs Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global COX-2 Selective NSAIDs Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global COX-2 Selective NSAIDs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global COX-2 Selective NSAIDs Manufacturers, Product Type & Application
- 3.7 Global COX-2 Selective NSAIDs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global COX-2 Selective NSAIDs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 COX-2 Selective NSAIDs Players Market Share by Revenue in 2024
- 3.8.3 2024 COX-2 Selective NSAIDs Tier 1, Tier 2, and Tier 3
- 4 COX-2 Selective NSAIDs Market by Type
- 4.1 COX-2 Selective NSAIDs Type Introduction
- 4.1.1 Valdecoxib
- 4.1.2 Rofecoxib
- 4.1.3 Celecoxib
- 4.1.4 Etoricoxib
- 4.2 Global COX-2 Selective NSAIDs Sales by Type
- 4.2.1 Global COX-2 Selective NSAIDs Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global COX-2 Selective NSAIDs Sales by Type (2020-2031)
- 4.2.3 Global COX-2 Selective NSAIDs Sales Market Share by Type (2020-2031)
- 4.3 Global COX-2 Selective NSAIDs Revenue by Type
- 4.3.1 Global COX-2 Selective NSAIDs Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global COX-2 Selective NSAIDs Revenue by Type (2020-2031)
- 4.3.3 Global COX-2 Selective NSAIDs Revenue Market Share by Type (2020-2031)
- 5 COX-2 Selective NSAIDs Market by Application
- 5.1 COX-2 Selective NSAIDs Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Other
- 5.2 Global COX-2 Selective NSAIDs Sales by Application
- 5.2.1 Global COX-2 Selective NSAIDs Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global COX-2 Selective NSAIDs Sales by Application (2020-2031)
- 5.2.3 Global COX-2 Selective NSAIDs Sales Market Share by Application (2020-2031)
- 5.3 Global COX-2 Selective NSAIDs Revenue by Application
- 5.3.1 Global COX-2 Selective NSAIDs Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global COX-2 Selective NSAIDs Revenue by Application (2020-2031)
- 5.3.3 Global COX-2 Selective NSAIDs Revenue Market Share by Application (2020-2031)
- 6 Global COX-2 Selective NSAIDs Sales by Region
- 6.1 Global COX-2 Selective NSAIDs Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global COX-2 Selective NSAIDs Sales by Region (2020-2031)
- 6.2.1 Global COX-2 Selective NSAIDs Sales by Region (2020-2025)
- 6.2.2 Global COX-2 Selective NSAIDs Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America COX-2 Selective NSAIDs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America COX-2 Selective NSAIDs Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe COX-2 Selective NSAIDs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe COX-2 Selective NSAIDs Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific COX-2 Selective NSAIDs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific COX-2 Selective NSAIDs Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa COX-2 Selective NSAIDs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa COX-2 Selective NSAIDs Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global COX-2 Selective NSAIDs Revenue by Region
- 7.1 Global COX-2 Selective NSAIDs Revenue by Region
- 7.1.1 Global COX-2 Selective NSAIDs Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global COX-2 Selective NSAIDs Revenue by Region (2020-2025)
- 7.1.3 Global COX-2 Selective NSAIDs Revenue by Region (2026-2031)
- 7.1.4 Global COX-2 Selective NSAIDs Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America COX-2 Selective NSAIDs Revenue (2020-2031)
- 7.2.2 North America COX-2 Selective NSAIDs Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe COX-2 Selective NSAIDs Revenue (2020-2031)
- 7.3.2 Europe COX-2 Selective NSAIDs Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific COX-2 Selective NSAIDs Revenue (2020-2031)
- 7.4.2 Asia-Pacific COX-2 Selective NSAIDs Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa COX-2 Selective NSAIDs Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa COX-2 Selective NSAIDs Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Teva
- 8.1.1 Teva Comapny Information
- 8.1.2 Teva Business Overview
- 8.1.3 Teva COX-2 Selective NSAIDs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Teva COX-2 Selective NSAIDs Product Portfolio
- 8.1.5 Teva Recent Developments
- 8.2 Merck
- 8.2.1 Merck Comapny Information
- 8.2.2 Merck Business Overview
- 8.2.3 Merck COX-2 Selective NSAIDs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Merck COX-2 Selective NSAIDs Product Portfolio
- 8.2.5 Merck Recent Developments
- 8.3 Mylan
- 8.3.1 Mylan Comapny Information
- 8.3.2 Mylan Business Overview
- 8.3.3 Mylan COX-2 Selective NSAIDs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Mylan COX-2 Selective NSAIDs Product Portfolio
- 8.3.5 Mylan Recent Developments
- 8.4 Jiangsu Hengrui Medicine
- 8.4.1 Jiangsu Hengrui Medicine Comapny Information
- 8.4.2 Jiangsu Hengrui Medicine Business Overview
- 8.4.3 Jiangsu Hengrui Medicine COX-2 Selective NSAIDs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Jiangsu Hengrui Medicine COX-2 Selective NSAIDs Product Portfolio
- 8.4.5 Jiangsu Hengrui Medicine Recent Developments
- 8.5 Pfizer
- 8.5.1 Pfizer Comapny Information
- 8.5.2 Pfizer Business Overview
- 8.5.3 Pfizer COX-2 Selective NSAIDs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Pfizer COX-2 Selective NSAIDs Product Portfolio
- 8.5.5 Pfizer Recent Developments
- 8.6 Lupin
- 8.6.1 Lupin Comapny Information
- 8.6.2 Lupin Business Overview
- 8.6.3 Lupin COX-2 Selective NSAIDs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Lupin COX-2 Selective NSAIDs Product Portfolio
- 8.6.5 Lupin Recent Developments
- 8.7 Apotex
- 8.7.1 Apotex Comapny Information
- 8.7.2 Apotex Business Overview
- 8.7.3 Apotex COX-2 Selective NSAIDs Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 Apotex COX-2 Selective NSAIDs Product Portfolio
- 8.7.5 Apotex Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 COX-2 Selective NSAIDs Value Chain Analysis
- 9.1.1 COX-2 Selective NSAIDs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 COX-2 Selective NSAIDs Production Mode & Process
- 9.2 COX-2 Selective NSAIDs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 COX-2 Selective NSAIDs Distributors
- 9.2.3 COX-2 Selective NSAIDs Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.